Why did Johnson & Johnson (NYSE:JNJ) receive FDA De Novo authorization?

Johnson & Johnson (NYSE:JNJ) secured FDA clearance because it developed the first table-integrated soft tissue robotic system. The device is authorized for multiple general surgery procedures, including gastric bypass and hernia repair.

How does the new robotic system alter capacity for Johnson & Johnson (NYSE:JNJ)?

The OTTAVA system developed by Johnson & Johnson (NYSE:JNJ) occupies 30 to 50 percent less footprint than traditional boom-mounted carts. This space reduction creates additional room for clinical teams to move and communicate during operations.

What are the automated features introduced by Johnson & Johnson (NYSE:JNJ)?

Johnson & Johnson (NYSE:JNJ) integrated automated software controls to coordinate its four table-mounted robotic arms. This twin motion technology enables patient repositioning and multi-quadrant access without requiring manual intraoperative adjustments.

What do the updated surgical instruments mean for Johnson & Johnson (NYSE:JNJ)?

The surgical tools produced by Johnson & Johnson (NYSE:JNJ) feature a two-in-one needle driver designed to reduce unintended suture cutting. The robotic system also includes monopolar curved scissors to deliver consistent tissue cuts.

What is the commercial rollout plan for Johnson & Johnson (NYSE:JNJ)?

Johnson & Johnson (NYSE:JNJ) will initially launch its robotic system with select hospital customers in the United States. The company is concurrently conducting an inguinal hernia clinical trial to secure additional regulatory clearances.

Image for illustrative purposes only. Not a real photo.

Johnson & Johnson earns FDA 4-arm robotics clearance

Written by Jon CuthbertPublished Jul 22, 2026, 12:44 PM

Johnson & Johnson secured FDA De Novo authorization for its four-arm OTTAVA robotic surgical system.
The table-integrated device is designed to occupy up to 50 percent less operating room space.
The company will launch the system with select customers while pursuing additional regulatory clearances.

Johnson & Johnson (NYSE:JNJ) secured FDA De Novo authorization for its four-arm OTTAVA robotic surgical system.

The new table-integrated platform occupies up to 50 percent less space than traditional boom-mounted surgical carts.

"We are pioneering a new category of surgical robotics with OTTAVA," said Johnson & Johnson Executive Vice President Tim Schmid.

The system is authorized for multiple general surgery procedures and features a two-in-one needle driver.

Management designed the technology with twin motion capabilities to enable patient repositioning without manual intraoperative adjustments.

The company stated that this digital architecture is expected to support continuous clinical education and data-driven surgical improvements.

Johnson & Johnson earns FDA 4-arm robotics clearance

Frequently asked questions

Assets related to this article